Amanta Healthcare Ltd is launching its Preliminary Public Providing (IPO) to strengthen capital expenditure necessities, help strategic growth, and for company functions. The IPO includes a totally recent situation of 1.00 crore shares aggregating to Rs. 126.00 crores with a face worth of Rs. 10 every.
The overall provide measurement aggregates as much as Rs. 126.00 crore. The IPO opens for subscription on September 1, 2025, and closes on September 3, 2025. The shares will probably be listed on each the NSE and the BSE after the IPO concludes.
GMP of Amanta Healthcare Ltd IPO
As of August twenty ninth, 2025, the shares of Amanta Healthcare Ltd within the gray market have been buying and selling at a 19.84 % premium. The shares within the Gray Market traded at Rs. 151. This offers it a premium of Rs. 25 per share over the cap value of Rs. 126.
Overview of Amanta Healthcare Ltd
Amanta Healthcare Restricted, Integrated in December 1994, is a pharmaceutical firm engaged within the growth, manufacturing, and advertising and marketing of sterile liquid formulations. It focuses on parenteral merchandise packaged utilizing superior applied sciences like Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM). The corporate additionally manufactures a spread of medical units.
Amanta’s product portfolio contains IV fluids, diluents, ophthalmic options, respiratory care merchandise, irrigation options, eye lubricants, and first-aid merchandise. These are manufactured throughout greater than 45 generic formulations and marketed beneath its personal manufacturers in India by way of a community of 320 distributors and stockists.
The corporate operates by way of three key enterprise segments: nationwide gross sales, worldwide gross sales, and strategic partnerships with Indian and international pharma corporations. It exports to markets in Africa, Latin America, the UK, and others, with product registrations in 19 international locations and branded exports to 21 international locations throughout FY25. As of March 31, 2025, Amanta Healthcare employed 1,718 personnel throughout its formulation growth, manufacturing, and high quality laboratories.
Promoters of Amanta Healthcare
The promoters of Amanta Healthcare Restricted are Bhavesh Patel, Vishal Patel, Jayshreeben Patel, Jitendrakumar Patel, and Milcent Home equipment Non-public Restricted, who’ve a long time of expertise within the pharmaceutical and healthcare sector. Their deep understanding of sterile manufacturing applied sciences, international regulatory compliance, and pharmaceutical product growth has been instrumental in driving the corporate’s progress.
Lead Managers of Amanta Healthcare IPO
Beeline Capital Advisors Non-public Restricted is appearing because the Guide Operating Lead Supervisor, whereas MUFG Intime India Non-public Restricted (previously Hyperlink Intime India Non-public Restricted) is serving because the Registrar, managing investor purposes and allotment.
Aims of the IPO Supply
The proceeds from Amanta Healthcare Restricted’s IPO will probably be primarily used to help the corporate’s manufacturing growth and operational enhancement efforts. A considerable portion, amounting to ₹70.00 crore, will probably be allotted in direction of funding capital expenditure for civil development and buying gear, plant, and equipment for establishing a brand new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat.
An extra ₹30.13 crore will probably be utilized for comparable capital expenditure in direction of establishing a brand new manufacturing line for Small Quantity Parenterals (SVP) on the identical location. The remaining proceeds will probably be used for common company functions, aiding the corporate’s ongoing enterprise progress and strategic initiatives.
Monetary Evaluation of Amanta Healthcare
The corporate has demonstrated a gentle monetary efficiency over the previous three years. Whole revenue stood at ₹262.70 crore in FY23, elevated barely to ₹281.61 crore in FY24 (a progress of seven.2%), however declined marginally to ₹276.09 crore in FY25, marking a 2% drop.
Regardless of the income fluctuations, the corporate’s profitability improved considerably. It posted a lack of ₹2.11 crore in FY23, turned worthwhile with ₹3.63 crore in FY24, and noticed PAT rise sharply to ₹10.50 crore in FY25, demonstrating sturdy turnaround and operational effectivity.
Amanta Healthcare Ltd Vs Friends
Amanta Healthcare Restricted reported a complete revenue of ₹276.09 crore. The corporate has restated primary and diluted earnings per share (EPS) of ₹3.71, a return on internet value (RoNW) of 10.89%, and a internet asset worth (NAV) per fairness share of ₹33.43, and the price-to-earnings (P/E) ratio and present market value (CMP) are usually not disclosed.
Their competitor, Denis Chem Lab Restricted, recorded a complete revenue of ₹175.67 crore with the. It has a better P/E ratio of 15.92 and a CMP of ₹92.65, indicating a stronger market valuation. The restated EPS is ₹5.82, with a RoNW of 9.49% and NAV per share of ₹61.33. In comparison with Amanta Healthcare, Denis Chem Lab reveals greater earnings per share, although Amanta has a barely higher return on internet value.
Amanta Healthcare Strengths and Weaknesses
Strengths:
- The corporate is a Effectively-established producer of pharmaceutical formulations with a various product portfolio and a various market.
- They’ve Massive manufacturing capabilities.
- The corporate has a Large Home and Worldwide Advertising and marketing Community.
- It has an skilled administration workforce supported by a big, numerous, and expert workforce.
Weak point:
Single Location Manufacturing Danger: The whole manufacturing is concentrated at one facility in Hariyala, Kheda, Gujarat. Any disruption on account of energy/water shortages, equipment failure, pure disasters, or different unexpected occasions may negatively impression manufacturing and enterprise operations.
Operational and High quality Dangers: Delays or points in manufacturing or high quality management could result in order cancellations, contract breaches, and lack of shoppers, adversely affecting income and money circulate. Authorized Danger: The corporate is concerned in ongoing materials litigation. An unfavorable end result may impression monetary situation and progress prospects.
Shareholder Exit Supply: The corporate has issued fairness shares to over 49 buyers previously and has offered an exit provide to eligible shareholders as a part of enhanced company governance.
Conclusion
Amanta Healthcare Ltd.’s IPO provides a promising alternative within the pharmaceutical sector. The corporate has a robust vary of merchandise, a rising worldwide presence, and has proven a superb restoration in income over the previous few years. Its plans to increase manufacturing capability additional strengthen its long-term progress potential. Total, the IPO may very well be a superb choice for these trying to put money into the healthcare house, but it surely’s essential to look fastidiously on the firm’s fundamentals and threat elements earlier than investing.
Written by Sridhar J
Disclaimer
The views and funding ideas expressed by funding specialists/broking homes/ranking businesses on tradebrains.in are their very own, and never that of the web site or its administration. Investing in equities poses a threat of monetary losses. Buyers should due to this fact train due warning whereas investing or buying and selling in shares. Commerce Brains Applied sciences Non-public Restricted or the creator are usually not chargeable for any losses prompted on account of the choice based mostly on this text. Please seek the advice of your funding advisor earlier than investing.
The publish Amanta Healthcare Ltd IPO: From situation particulars to financials; Right here’s what you might want to know appeared first on Commerce Brains.
